208 related articles for article (PubMed ID: 20652971)
1. TG101209, a novel JAK2 inhibitor, has significant in vitro activity in multiple myeloma and displays preferential cytotoxicity for CD45+ myeloma cells.
Ramakrishnan V; Kimlinger T; Haug J; Timm M; Wellik L; Halling T; Pardanani A; Tefferi A; Rajkumar SV; Kumar S
Am J Hematol; 2010 Sep; 85(9):675-86. PubMed ID: 20652971
[TBL] [Abstract][Full Text] [Related]
2. INCB16562, a JAK1/2 selective inhibitor, is efficacious against multiple myeloma cells and reverses the protective effects of cytokine and stromal cell support.
Li J; Favata M; Kelley JA; Caulder E; Thomas B; Wen X; Sparks RB; Arvanitis A; Rogers JD; Combs AP; Vaddi K; Solomon KA; Scherle PA; Newton R; Fridman JS
Neoplasia; 2010 Jan; 12(1):28-38. PubMed ID: 20072651
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of JAK2 signaling by TG101209 enhances radiotherapy in lung cancer models.
Sun Y; Moretti L; Giacalone NJ; Schleicher S; Speirs CK; Carbone DP; Lu B
J Thorac Oncol; 2011 Apr; 6(4):699-706. PubMed ID: 21325979
[TBL] [Abstract][Full Text] [Related]
4. Heat shock protein 90 inhibitor is synergistic with JAK2 inhibitor and overcomes resistance to JAK2-TKI in human myeloproliferative neoplasm cells.
Fiskus W; Verstovsek S; Manshouri T; Rao R; Balusu R; Venkannagari S; Rao NN; Ha K; Smith JE; Hembruff SL; Abhyankar S; McGuirk J; Bhalla KN
Clin Cancer Res; 2011 Dec; 17(23):7347-58. PubMed ID: 21976548
[TBL] [Abstract][Full Text] [Related]
5. An activated JAK/STAT3 pathway and CD45 expression are associated with sensitivity to Hsp90 inhibitors in multiple myeloma.
Lin H; Kolosenko I; Björklund AC; Protsyuk D; Österborg A; Grandér D; Tamm KP
Exp Cell Res; 2013 Mar; 319(5):600-11. PubMed ID: 23246572
[TBL] [Abstract][Full Text] [Related]
6. TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.
Pardanani A; Hood J; Lasho T; Levine RL; Martin MB; Noronha G; Finke C; Mak CC; Mesa R; Zhu H; Soll R; Gilliland DG; Tefferi A
Leukemia; 2007 Aug; 21(8):1658-68. PubMed ID: 17541402
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis.
Alas S; Bonavida B
Clin Cancer Res; 2003 Jan; 9(1):316-26. PubMed ID: 12538484
[TBL] [Abstract][Full Text] [Related]
8. The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival.
Scuto A; Krejci P; Popplewell L; Wu J; Wang Y; Kujawski M; Kowolik C; Xin H; Chen L; Wang Y; Kretzner L; Yu H; Wilcox WR; Yen Y; Forman S; Jove R
Leukemia; 2011 Mar; 25(3):538-50. PubMed ID: 21164517
[TBL] [Abstract][Full Text] [Related]
9. Cantharidin induces apoptosis of human multiple myeloma cells via inhibition of the JAK/STAT pathway.
Sagawa M; Nakazato T; Uchida H; Ikeda Y; Kizaki M
Cancer Sci; 2008 Sep; 99(9):1820-6. PubMed ID: 18544087
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of JAK1/STAT3 signaling mediates compound K-induced apoptosis in human multiple myeloma U266 cells.
Park S; Lee HJ; Jeong SJ; Song HS; Kim M; Lee HJ; Lee EO; Kim DH; Ahn KS; Kim SH
Food Chem Toxicol; 2011 Jun; 49(6):1367-72. PubMed ID: 21420464
[TBL] [Abstract][Full Text] [Related]
11. Targeting receptor kinases by a novel indolinone derivative in multiple myeloma: abrogation of stroma-derived interleukin-6 secretion and induction of apoptosis in cytogenetically defined subgroups.
Bisping G; Kropff M; Wenning D; Dreyer B; Bessonov S; Hilberg F; Roth GJ; Munzert G; Stefanic M; Stelljes M; Scheffold C; Müller-Tidow C; Liebisch P; Lang N; Tchinda J; Serve HL; Mesters RM; Berdel WE; Kienast J
Blood; 2006 Mar; 107(5):2079-89. PubMed ID: 16278310
[TBL] [Abstract][Full Text] [Related]
12. Fibroblast growth factor-2 and -4 promote the proliferation of bone marrow mesenchymal stem cells by the activation of the PI3K-Akt and ERK1/2 signaling pathways.
Choi SC; Kim SJ; Choi JH; Park CY; Shim WJ; Lim DS
Stem Cells Dev; 2008 Aug; 17(4):725-36. PubMed ID: 18788932
[TBL] [Abstract][Full Text] [Related]
13. Emodin has a cytotoxic activity against human multiple myeloma as a Janus-activated kinase 2 inhibitor.
Muto A; Hori M; Sasaki Y; Saitoh A; Yasuda I; Maekawa T; Uchida T; Asakura K; Nakazato T; Kaneda T; Kizaki M; Ikeda Y; Yoshida T
Mol Cancer Ther; 2007 Mar; 6(3):987-94. PubMed ID: 17363492
[TBL] [Abstract][Full Text] [Related]
14. Anti-myeloma effects of ruxolitinib combined with bortezomib and lenalidomide: A rationale for JAK/STAT pathway inhibition in myeloma patients.
de Oliveira MB; Fook-Alves VL; Eugenio AIP; Fernando RC; Sanson LFG; de Carvalho MF; Braga WMT; Davies FE; Colleoni GWB
Cancer Lett; 2017 Sep; 403():206-215. PubMed ID: 28645562
[TBL] [Abstract][Full Text] [Related]
15. Preclinical activity of DCZ3301, a novel aryl-guanidino compound in the therapy of multiple myeloma.
Gao M; Li B; Sun X; Zhou Y; Wang Y; Tompkins VS; Xu Z; Indima N; Wang H; Xiao W; Gao L; Chen G; Wu H; Wu X; Kong Y; Xie B; Zhang Y; Chang G; Hu L; Yang G; Dai B; Tao Y; Zhu W; Shi J
Theranostics; 2017; 7(15):3690-3699. PubMed ID: 29109769
[TBL] [Abstract][Full Text] [Related]
16. AZ960, a novel Jak2 inhibitor, induces growth arrest and apoptosis in adult T-cell leukemia cells.
Yang J; Ikezoe T; Nishioka C; Furihata M; Yokoyama A
Mol Cancer Ther; 2010 Dec; 9(12):3386-95. PubMed ID: 21159615
[TBL] [Abstract][Full Text] [Related]
17. Embelin suppresses STAT3 signaling, proliferation, and survival of multiple myeloma via the protein tyrosine phosphatase PTEN.
Heo JY; Kim HJ; Kim SM; Park KR; Park SY; Kim SW; Nam D; Jang HJ; Lee SG; Ahn KS; Kim SH; Shim BS; Choi SH; Ahn KS
Cancer Lett; 2011 Sep; 308(1):71-80. PubMed ID: 21565443
[TBL] [Abstract][Full Text] [Related]
18. Janus activated kinase 2/signal transducer and activator of transcription 3 pathway mediates icariside II-induced apoptosis in U266 multiple myeloma cells.
Kim SH; Ahn KS; Jeong SJ; Kwon TR; Jung JH; Yun SM; Han I; Lee SG; Kim DK; Kang M; Chen CY; Lee JW; Kim SH
Eur J Pharmacol; 2011 Mar; 654(1):10-6. PubMed ID: 21172343
[TBL] [Abstract][Full Text] [Related]
19. Pro-Apoptotic Activity of Ruxolitinib Alone and in Combination with Hydroxyurea, Busulphan, and PI3K/mTOR Inhibitors in JAK2-Positive Human Cell Lines.
Szymańska J; Smolewski P; Majchrzak A; Cebula-Obrzut B; Chojnowski K; Treliński J
Adv Clin Exp Med; 2015; 24(2):195-202. PubMed ID: 25931349
[TBL] [Abstract][Full Text] [Related]
20. SWIM domain protein ZSWIM4 is required for JAK2 inhibition resistance in breast cancer.
Gong K; Song K; Zhu Z; Xiang Q; Wang K; Shi J
Life Sci; 2021 Aug; 279():119696. PubMed ID: 34102191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]